CeriBell (NASDAQ:CBLL) Shares Cross Above 50-Day Moving Average – Should You Sell?

CeriBell, Inc. (NASDAQ:CBLL – Get Free Report)’s stock price passed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $25.66 and traded as high as $26.00. CeriBell shares last traded at $25.75, with a volume of 537,237 shares changing hands.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on CBLL shares. Raymond James Financial reissued a “strong-buy” rating and issued a $29.00 price target on shares of CeriBell in a report on Thursday, September 3rd. Canaccord Genuity Group upped their price objective on shares of CeriBell from $26.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. BTIG Research reiterated a “buy” rating on shares of CeriBell in a report on Wednesday, November 4th. Finally, Barclays upgraded CeriBell to a “neutral” rating in a report on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, CeriBell has an average rating of “Moderate Buy” and a consensus price target of $31.25.

Read Our Latest Research Report on CBLL

CeriBell Trading Up 6.1%

The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -14.09 and a beta of 0.86. The company has a debt-to-equity ratio of 0.17, a current ratio of 8.18 and a quick ratio of 7.79. The business has a 50-day moving average of $25.73 and a 200-day moving average of $21.18.

CeriBell (NASDAQ:CBLL – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). CeriBell had a negative net margin of 67.96% and a negative return on equity of 52.59%. The firm had revenue of $29.34 million during the quarter, compared to the consensus estimate of $29.18 million. Research analysts anticipate that CeriBell, Inc. will post -2.05 EPS for the current year.

Insider Activity

In related news, CEO Xingjuan Chao sold 20,846 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $25.03, for a total value of $521,775.38. Following the completion of the sale, the chief executive officer directly owned 746,345 shares in the company, valued at $18,681,015.35. The trade was a 2.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Joseph Taylor sold 10,200 shares of the business’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $27.22, for a total transaction of $277,644.00. Following the completion of the sale, the director directly owned 38,278 shares of the company’s stock, valued at approximately $1,041,927.16. The trade was a 21.04% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 139,859 shares of company stock valued at $3,554,775. Company insiders own 17.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CBLL. Sei Investments Co. lifted its holdings in shares of CeriBell by 2.3% in the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after acquiring an additional 1,125 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of CeriBell during the 2nd quarter valued at approximately $53,000. State of Wyoming bought a new stake in shares of CeriBell during the 1st quarter valued at approximately $62,000. Quantinno Capital Management LP increased its position in CeriBell by 3.0% during the 1st quarter. Quantinno Capital Management LP now owns 140,347 shares of the company’s stock worth $2,573,000 after purchasing an additional 4,119 shares in the last quarter. Finally, Wellington Management Group LLP increased its position in CeriBell by 5.5% during the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after purchasing an additional 4,572 shares in the last quarter.

CeriBell Company Profile

(Get Free Report)

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.

Recommended Stories

Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.